| Expression pattern: |
UP |
| Associated gene: |
HOXA9 |
| Associated microRNA: |
miR-641 |
| Biological function: |
promotes cisplatin chemoresistance and stemness; its knock-down sensitizes DDP-resistant NSCLC cells to cisplatin and inhibits stemness |
| Molecular mechanism: |
ceRNA (RNA sponge): circRNA CDR1as sponges miR-641 to upregulate HOXA9, affecting stemness and cisplatin resistance |
| Biological pathway or process: |
stemness (promotes); chemoresistance (promotes); ceRNA regulation (promotes); proliferation (promotes); apoptosis (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Luciferase Reporter Assay; RNA Pull-Down; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; IHC (Immunohistochemistry); Bioinformatics Analysis |
| Clinical significance: |
- |
| Description: |
In NSCLC cisplatin-resistant models, circRNA CDR1as is up-regulated and promotes cisplatin chemoresistance and cancer stemness. It functions as a ceRNA by sponging miR-641 to increase HOXA9 expression; CDR1as knockdown sensitizes resistant cells to cisplatin and reduces stemness via the miR-641/HOXA9 axis. |
| Confidence score: |
0.7045 |